- Home
- TXMD vs AYTU Comparison
TXMD vs AYTU Comparison
Compare TXMD & AYTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | AYTU |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 27.4M |
| IPO Year | 2012 | 2015 |
Fundamental Metrics
Financial Performance| Metric | TXMD | AYTU |
|---|---|---|
| Price | $2.06 | $2.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 29.0K | 25.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | $1,761,000.00 | ★ $27,632,080.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $43.75 |
| P/E Ratio | $206.00 | ★ N/A |
| Revenue Growth | 35.25 | ★ 277.47 |
| 52 Week Low | $0.99 | $1.65 |
| 52 Week High | $2.95 | $3.07 |
Technical Indicators
Market Signals| Indicator | TXMD | AYTU |
|---|---|---|
| Relative Strength Index (RSI) | 51.47 | 46.84 |
| Support Level | $1.90 | $2.11 |
| Resistance Level | $2.09 | $2.31 |
| Average True Range (ATR) | 0.12 | 0.06 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 31.78 | 31.58 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About AYTU Aytu BioPharma Inc.
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.